[Assessment of prognostic value of some antigens: p53, bcl-2 and syndecan-1 in laryngeal cancer as well as determination of the usefulness of these antigens in presenting response to cisplatinum in primary cellular cultures of laryngeal cancer].
Klatka
Janusz
J
Katedra i Klinika Otolaryngologii i Onkologii Laryngologicznej AM w Lublinie.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000276:immunology*; D011379:Prognosis; D011509:Proteoglycans / Q000276:immunology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000276:immunology*; D053668:Syndecan-1; D053667:Syndecans; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins; D011509:Proteoglycans; D019253:Proto-Oncogene Proteins c-bcl-2; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin